Optimizing Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration: the Potential Value of Sustained Anti-VEGF Therapy.
Ophthalmic Surg Lasers Imaging Retina
; 54(11): 654-659, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-37956321
ABSTRACT
Neovascular age-related macular degeneration (nAMD) leads to irreversible central vision loss if untreated. Frequent administration of anti-vascular endothelial growth factor (anti-VEGF) injections inhibits disease activity with excellent functional and morphological benefits. However, these injections pose a heavy therapeutic burden, and treatment discontinuation is common. Although current anti-VEGF treatment paradigms, such as treat-and-extend, mitigate treatment burden while still leading to acceptable vision outcomes, they fail to sustain initial vision gains for many. Novel longer-acting anti-VEGF therapies may reduce the overall burden on nAMD patients. Gene therapy might offer a paradigm shift by providing continuous expression of anti-VEGF, potentially decreasing treatment requirements and improving long-term vision outcomes. [Ophthalmic Surg Lasers Imaging Retina 2023;54654-659.].
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Choroidal Neovascularization
/
Wet Macular Degeneration
/
Macular Degeneration
Limits:
Humans
Language:
En
Journal:
Ophthalmic Surg Lasers Imaging Retina
Year:
2023
Document type:
Article